HPV vaccine acceptability in heterosexual, gay, and bisexual men.
We know little about men's beliefs about human papillomavirus (HPV) vaccine and willingness to receive it. In January 2009, the authors recruited 296 heterosexual men and 312 gay and bisexual men from a national panel of U.S. households to complete an online survey about HPV and HPV vaccine. The authors analyzed data using logistic regression, controlling for age, education, number of lifetime sexual partners, and urban residence. More gay and bisexual men than heterosexual men were willing to receive HPV vaccine (73% vs. 37%; adjusted odds ratio = 4.99; 95% confidence interval = 3.36, 7.49). Gay and bisexual men reported greater awareness of HPV vaccine, perceived worry about HPV-related diseases, perceived effectiveness of HPV vaccine, and anticipated regret if they declined vaccination and later developed HPV-related disease compared with heterosexual men (all ps < .05). The lower acceptability and different beliefs among heterosexual men suggest that novel interventions for this group may be needed.
Gilbert
Paul
P
UNC Gillings School of Global Public Health, Chapel Hill, NC 27599, USA. paul.gilbert@unc.edu
Brewer
Noel T
NT
Reiter
Paul L
PL
Ng
Terence W
TW
Smith
Jennifer S
JS
D000293:Adolescent; D000328:Adult; D001727:Bisexuality / Q000523:psychology*; D016001:Confidence Intervals; D003258:Consumer Behavior; D007722:Health Knowledge, Attitudes, Practice; D020010:Heterosexuality / Q000523:psychology*; D018451:Homosexuality, Male / Q000523:psychology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D054526:Men's Health; D008875:Middle Aged; D016017:Odds Ratio; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000600:supply & distribution*; D010465:Perception; D014481:United States / Q000453:epidemiology; D055815:Young Adult
D053918:Papillomavirus Vaccines
J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7
18809147
N Engl J Med. 1987 Oct 15;317(16):973-7
2821396
Cancer Causes Control. 2009 May;20(4):449-57
19082746
Int J Cancer. 2009 May 15;124(10):2375-83
19189402
Sex Transm Dis. 2007 Mar;34(3):170-3
16837830
Sex Transm Dis. 2009 Jan;36(1):58-62
18830138
J Infect Dis. 2006 Oct 15;194(8):1044-57
16991079
J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31
2810388
J Am Coll Health. 2008 Jul-Aug;57(1):23-32
18682342
Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S24-6
17938015
J Low Genit Tract Dis. 2008 Oct;12(4):276-81
18820541
J Womens Health (Larchmt). 2008 May;17(4):539-48
18370586
J Pathol. 1999 Sep;189(1):12-9
10451482
J Adolesc Health. 2010 Feb;46(2):113-23
20113917
Cancer. 2008 Nov 15;113(10 Suppl):3036-46
18980286
Int J STD AIDS. 2005 Oct;16(10):707-8
16212721
J Adolesc Health. 2008 Oct;43(4 Suppl):S52-60
18809146
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
17380109
Vaccine. 2008 Aug 19;26 Suppl 10:K17-28
18847554
J Infect Dis. 2008 Sep 15;198(6):827-35
18657037
Clin Infect Dis. 2006 Sep 1;43(5):624-9
16886157
Prev Med. 2007 Aug-Sep;45(2-3):107-14
17628649
Sex Transm Infect. 2009 Apr;85(2):148-9
19153110
N Engl J Med. 1997 Nov 6;337(19):1350-8
9358129
Sex Transm Infect. 2010 Jun;86(3):241-6
19951936
Curr HIV/AIDS Rep. 2008 May;5(2):78-85
18510893
Aust Nurs J. 2008 Sep;16(3):33
18841719
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):805-8
18398020
Sex Transm Dis. 2010 Mar;37(3):197-203
20118831
J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42
19124631